



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

August 16, 2023

ADVISORY

**Review of Administrative Order No. 2019-0041 dated October 4, 2019 titled
“Implementing Guidelines in Assuring the Efficacy, Quality and Safety of
Pharmaceutical Products in the Public Health Facilities”**

The Administrative Order (AO) No. 2019-0041 entitled, *“Implementing Guidelines in Assuring the Efficacy, Quality and Safety of Pharmaceutical Products in the Public Health Facilities”* was issued on October 4, 2019 to set the implementing guidelines in assuring the safety, efficacy, and quality of pharmaceutical products along the entire supply chain in all public health facilities. Please be informed that the said AO will be undergoing a review to align with the latest policies issued by the DOH.

Recently, there were some challenges regarding the implementation of certain provisions of the said AO particularly on securing the influenza polyvalent vaccine (Flu vaccine) and other vaccines. With this, there is a recent directive to review the said AO to align with the latest policies issued by the DOH and to recommend necessary policy revision/s.

In this regard, we would like to request for the comments, input and/or recommendation of your office on the rescission and/or revision of certain provisions of the issuance. Kindly follow the prescribed format below in submitting your recommendations:

Recommendation on the Rescission / Revision of AO 2019-0041

Name of Office: _____

Recommendation:

- RESCIND the AO. Comments, if any: _____
- RESCIND Certain Provision/s. Please specify provision/s, if any: _____
- AMEND Certain Provision/s. Please specify provision/s and indicate proposed amendment/s: _____

We will highly appreciate it if you can submit your comments, input and/or recommendations **on or before August 25, 2023** through email at ssupd@doh.gov.ph / vsobera@doh.gov.ph or through uploading your signed response through this link: <https://bit.ly/DOHAO2019-0041>

Thank you.

FIDES MARIA AILEEN V. BUENAFE, MD
Chief, Pharmaceutical Division